Stephanie Bass returns to review the management of HRS, focusing on HRS-AKI, before discussing the novel vasopressor, terlipressin.

Today’s episode features the return of Stephanie Bass, to highlight our favorite organ: the liver. Specifically we review the management of hepatorenal syndrome, or HRS. What is the new definition/nomenclature? Why was it updated? How does AKI differ from HRS-AKI?

Before getting into the specific treatments, focusing on albumin and vasoconstrictor treatment. What has albumin treatment been shown to do? How much to give? Any time we alter the recommended regimen?

The discussion shifts to vasoconstrictor therapy, and specifically the use of the novel vasopressor: terlipressin. What did the CONFIRM study show us? Any special considerations or adverse effects? How do we dose terlipressin? What is our ultimate treatment goal? Can we use terlipressin again if HRS is recurrent? Preferred alternate agents? Medication safety considerations, take-home points, and so much more are covered in this great episode.